General description:
Tumor susceptibility 101 (TSG101) is encoded by the gene mapped to human chromosome 11p15.1–15.2. The encoded protein is a member of catalytically inactive ubiquitin E2 variant (UEV) family. Tsg101 is characterized with an ubiquitin E2 variant (UEV) domain in its N-terminal end involved in HIV-1 budding and the vacuolar protein sorting (VPS) pathway.
Immunogen:
syntheitic peptide corresponding to amino acids 254-272 located near the C-terminus of human TSG101, conjugated to KLH. This sequence is identical in rat and mouse TSG101.
Biological source:
rabbit
Quality Level:
200
Conjugate:
unconjugated
Antibody form:
affinity isolated antibody
Antibody product type:
primary antibodies
Clone:
polyclonal
Form:
buffered aqueous solution
Mol wt:
antigen 46 kDa
Species reactivity:
rat, human, mouse
Concentration:
~2 mg/mL
Technique(s):
western blot: 0.5-1 μg/mL using cell lysates of rat fibroblast Rat-1 and mouse fibroblast NIH3T3 cells
western blot: 2-4 μg/mL using cell lysates of human A431 cells
UniProt accession no.:
Q99816
Shipped in:
dry ice
Storage temp.:
−20°C
Application:
Anti-TSG101 antibody produced in rabbit has been used in western blot analysis.
Biochem/physio Actions:
Tumor susceptibility 101 (TSG101) is implicated in various cellular function such as, ubiquitination, transcriptional regulation, endosomal trafficking and cell proliferation. Mutation in the gene leads to various human cancers.Tsg101 plays a crucial role in cell growth, cell survival, and normal function of embryonic and adult tissues. TSG101 facilitates infectious human immunodeficiency virus (HIV-1) budding by linking the p6 late domain to vacuolar protein sorting machinery. Tsg101 is a vital constituent of the endosomal sorting complex required for transport (ESCRT) machinery, that helps in synthesis of multi-vesicular bodies, mainly the formation and scission of the intraluminal vesicles, and is thus, crucial for the degradation and recycling of receptors localized on plasma membrane. Tsg101 expression is controlled by an intrinsic autoregulatory mechanism and by ubiquitination catalyzed by various ubiquitin ligases.
Physical form:
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium axide.
Disclaimer:
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.